Kevin Zent, MD
Family Medicine · Somersworth, NHNPI 1255380648
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 46.2% of the total. 2025 is the largest year on record at $772, more than ten times the $55 reported in 2019. Among family medicine clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Gilead$326
- Axsome Therapeutics, Inc.$159
- Baxter Healthcare$121
- Pfizer$91
- Braeburn Inc.$88
- plus $700 from 21 others
What the payments were for
- Food & beverage$2,758100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 100 | $1,275 |
| Gilead | 16 | $326 |
| Axsome Therapeutics, Inc. | 8 | $159 |
| Baxter Healthcare | 2 | $121 |
| Pfizer | 6 | $91 |
| Braeburn Inc. | 4 | $88 |
| Lilly USA, LLC | 4 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Novo Nordisk | 3 | $57 |
| Ironshore Pharmaceuticals Inc. | 3 | $56 |
| Boehringer Ingelheim | 3 | $47 |
| Alkermes, Inc. | 1 | $43 |
| Vanda Pharmaceuticals Inc. | 1 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $36 |
| GSK | 2 | $32 |
| Daiichi Sankyo Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $25 |
| VBI Vaccine (delaware) Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| Indivior Inc. | 1 | $21 |
| Merck | 1 | $21 |
| AstraZeneca | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
How this compares
$2,758 in reported general payments places this provider in the 90th percentile of 397 family medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 99 | $135,497 |
| OzempicSemaglutide | 71 | $107,339 |
| XareltoRivaroxaban | 36 | $57,587 |
| TrulicityDulaglutide | 35 | $55,227 |
| RybelsusSemaglutide | 14 | $32,104 |
| EliquisApixaban | 34 | $31,249 |
| SublocadeBuprenorphine | 14 | $28,679 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $28,076 |
| MyrbetriqMirabegron | 36 | $27,442 |
| VivitrolNaltrexone Microspheres | 15 | $24,919 |
| TrintellixVortioxetine Hydrobromide | 17 | $23,908 |
| MounjaroTirzepatide | 22 | $22,089 |
| VraylarCariprazine Hcl | 11 | $20,393 |
| Spiriva RespimatTiotropium Bromide | 19 | $17,862 |
| Spiriva HandihalerTiotropium Bromide | 13 | $16,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $47 | $153,359118 claims |
| Novo NordiskOzempic, Rybelsus | $57 | $139,44485 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $83 | $77,31757 claims |
| Johnson & JohnsonXarelto | $21 | $57,58736 claims |
| PfizerEliquis | $91 | $31,24934 claims |
| Indivior Inc.Sublocade | $21 | $28,67914 claims |
| GSKTrelegy Ellipta | $32 | $28,07631 claims |
| Alkermes, Inc.Vivitrol | $43 | $24,91915 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $17 | $24,74540 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $67 | $23,90817 claims |
| AbbVieVraylar | $1,275 | $20,39311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 397 family medicine providers in New Hampshire.
Other family medicine in Somersworth
- Mark BallentynePortsmouth$135K
- M LauterPortsmouth$21K
- Brian SponsellerNorth Conway$15K
- Cecilia Vicuna KeadyCharlestown$13K
- Keenan Al-HojerryPortsmouth$11K
- Peter LoeserConcord$10K
- Robyn StewartDerry$8K
- Robert KellyExeter$8K
- Dennis BadmanSanbornville$7K
- Ajay KoshyBedford$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.